Dose-response study for the highly aggressive and metastatic primary F3II mammary carcinoma under direct current med./bio.

By: González MM, Morales DF, Cabrales LEB, Pérez DJ, Montijano JI, Castañeda ARS, González VGS, Posada OO, Martínez JA, Delgado AG, Martínez KG, Mon ML, Monzón KL, Ciria HMC, Beatón EO, Brooks SCA, González TR, Jarque MV, Mateus MAÓ, Rodríguez JLG, Calzado EM